PAM Immunoassay for Bodily Fluid Diagnostic Quantification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting PAM activity in human body fluids lack direct measurement of PAM concentrations, which hinders their use in diagnosing, predicting, or monitoring diseases such as dementia, cardiovascular disorders, and cancer.
Innovation Solution
A method involving the determination of peptidylglycine alpha-amidating monooxygenase (PAM) and its isoforms or fragments in bodily fluid samples using immunoassays, comparing the levels to predetermined thresholds for disease diagnosis, prognosis, or adverse event prediction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current methods for detecting PAM activity are used, then PAM activity can be detected in human body fluids, but direct measurement of PAM concentrations is not achieved, hindering diagnostic use
Solution Approach 1:
The patent replaces traditional activity-based detection methods with immunoassay technology that directly measures PAM protein concentrations. This substitution enables quantitative concentration measurement rather than indirect activity assessment, providing the precise concentration data needed for reliable disease diagnosis and monitoring.
Solution Approach 2:
The patent introduces specific antibodies as intermediaries to detect and quantify PAM concentrations in body fluids. These antibodies serve as mediators that bind specifically to PAM, enabling accurate concentration measurement through immunoassay techniques, thereby bridging the gap between detecting PAM presence and achieving precise concentration quantification for diagnostic purposes.
2Reliability
If PAM levels are quantified using immunoassays, then accurate diagnosis and prognosis becomes possible, but the complexity of the detection method increases
Solution Approach 1:
The patent develops immunoassay methods using antibodies that can detect multiple PAM isoforms (full-length and truncated variants) simultaneously. This multi-functionality allows a single assay system to provide comprehensive PAM quantification across different disease states, maintaining high diagnostic accuracy while reducing the need for multiple separate detection methods.
Solution Approach 2:
The patent optimizes immunoassay parameters including antibody selection, incubation conditions, and detection thresholds to balance measurement accuracy with operational simplicity. By carefully adjusting these parameters, the method achieves reliable diagnostic accuracy while minimizing procedural complexity and making the assay more suitable for clinical implementation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate diagnosis, prognosis, and monitoring of diseases by quantifying PAM levels, improving predictive capabilities for conditions like Alzheimer's disease, colorectal cancer, and cardiovascular disorders.
Implementation Method 1
A method involving the determination of peptidylglycine alpha-amidating monooxygenase (PAM) and its isoforms or fragments in bodily fluid samples using immunoassays
Data Source
AI summary
The present invention is directed to a method for diagnosis or prognosis of a disease in a subject and/or predicting a risk of getting a disease or adverse event in a subject and/or monitoring a disease or adverse event in a subject by determining the level of peptidylglycine alpha-amidating monooxygenase (PAM) and/or its isoforms and/or fragments thereof in a sample of bodily fluid of said subject.